Molecular Signatures of Lung Cancer
- 36 Downloads
Molecular profiling holds great promise for improving our ability to diagnose, prognosticate, and select individualized treatments for lung cancer patients. However, using multidimensional data and novel technologies to derive these profiles is limited by our ability to employ the assay in a clinical scenario where it can impact the course of disease. Although many molecular signatures have been reported in lung cancer, as of yet, few have been sufficiently validated for widespread clinical use. Recently, several novel signatures have been reported, which address critical aspects of patient care and/or demonstrate improved efforts for appropriate clinical validation. Here, we present our opinion on the current state of the field of molecular signatures in lung cancer.
J.M.B. is a cofounder, vice president, and shareholder of TrackFive Diagnostics, Inc. C.L.A. has no conflicts of interest that are directly relevant to the content of this article.
- 8.Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007 Jan 4; 356 (1): 11–20Google Scholar
- 24.National Comprehensive Cancer Network. NCCN practice guidelines in oncology: small cell lung cancer [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf [Accessed 2012 Jan 20]
- 25.National Comprehensive Cancer Network. NCCN practice guidelines in oncology: non-small cell lung cancer [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf [Accessed 2012 Jan 20]
- 33.Azuma K, Okamoto I, Kawahara A, et al. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol 2012 Jan; 7(1): 122–7PubMedCrossRefGoogle Scholar
- 41.Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007 Jun 6; 99(11): 838–46PubMedCrossRefGoogle Scholar
- 45.Simon GR, Schell MJ, Begum M, et al. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. Epub 2011 Oct 25Google Scholar